PARP1 and cancer: Exploitation of the dysregulation of the DDR by synthetic lethality through the single-agent use of inhibitors of other DDR components, exemplified by the cytotoxicity of PARP inhibitors in HRR-defective tumours [8] is an exciting new paradigm in cancer that led to a rapid expansion in PARP inhibitor development.